STAT6-D419 mutations were recognized as the gain of function mutations owing to the increased nuclear localization of STAT6, upregulated STAT6-targeted gene expression, and increased sensitivity to JAK2 inhibitors of STAT6-D419-mutated lymphomas [120–122]. This evidence concerns the gene STAT6 and lymphoma.